gil dina的个人主页 - 老虎社区

gil dina

gil dina

暂无个人介绍

IP属地：未知

13关注

4粉丝

0主题

0勋章

2021-12-24

Nice

Singapore Stock Market Has A Green Light For Friday's Trade

2021-12-24

Like

U.S. authorizes Merck pill as second at-home COVID-19 treatment

2021-12-24

Like

SEC Spurns Crypto Industry Again, Denying Two Spot-Bitcoin ETFs

2021-12-23

Like

Wall St mints strong gains on rosy economic data, encouraging Omicron update

2021-12-23

Oh no

Biogen shares fell 1.2% in early trading

2021-12-23

Like

Britain approves Pfizer-BioNTech shot for younger children

2021-12-23

Like

Tesla, authorities submit documents for German plant approval

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":4101174879260110,"uuid":"4101174879260110","gmtCreate":1638609533809,"gmtModify":1640224017200,"name":"gil dina","pinyin":"gildinagildina","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/f87f0548663e1e1e6cfee22d9a835013","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":4,"headSize":13,"tweetSize":7,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":698389672,"gmtCreate":1640305061243,"gmtModify":1640305284888,"author":{"id":"4101174879260110","authorId":"4101174879260110","name":"gil dina","avatar":"https://static.tigerbbs.com/f87f0548663e1e1e6cfee22d9a835013","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/698389672","repostId":"1125729979","repostType":4,"repost":{"id":"1125729979","pubTimestamp":1640304436,"share":"https://www.laohu8.com/m/news/1125729979?lang=&edition=full","pubTime":"2021-12-24 08:07","market":"sg","language":"en","title":"Singapore Stock Market Has A Green Light For Friday's Trade","url":"https://stock-news.laohu8.com/highlight/detail?id=1125729979","media":"RTTNews","summary":"The Singapore stock market has finished higher in three straight sessions, gathering almost 25 point","content":"<p>The Singapore stock market has finished higher in three straight sessions, gathering almost 25 points or 0.8 percent along the way. The Straits Times Index now sits just above the 3,095-point plateau and it may extend its gains on Friday.</p>\n<p>The global forecast for the Asian&nbsp;markets&nbsp;is upbeat on easing virus concerns, rising crude oil prices and solid economic data. The European and U.S. markets were up and the Asian markets are expected to open in similar fashion.</p>\n<p>The STI finished modestly higher on Thursday following gains from the financial shares, property stocks and plantations.</p>\n<p>For the day, the index rose 9.30 points or 0.30 percent to finish at 3,096.81 after trading between 3,090.25 and 3,104.18. Volume was 878.5 million shares worth S$515.8 million. There were 265 gainers and 169 decliners.</p>\n<p>Among the actives, Ascendas REIT fell 0.34 percent, while CapitaLand Integrated Commercial Trust and Mapletree Commercial Trust both gained 0.51 percent, City Developments jumped 0.76 percent, Comfort DelGro climbed 0.74 percent, Dairy Farm International surged 2.23 percent, DBS Group increased 0.37 percent, Genting Singapore advanced 0.66 percent, Hongkong Land rallied 1.17 percent, Keppel Corp rose 0.39 percent, Mapletree Logistics Trust added 0.54 percent, Oversea-Chinese Banking Corporation collected 0.44 percent, SATS accelerated 1.32 percent, SembCorp Industries shed 0.50 percent, Singapore Airlines spiked 1.45 percent, Singapore Exchange was up 0.11 percent, Singapore Press Holdings lost 0.43 percent, Thai Beverage sank 0.75 percent, Wilmar International soared 1.50 percent and Yangzijiang Shipbuilding, Singapore Technologies Engineering, United Overseas Bank and SingTel were unchanged.</p>\n<p>The lead from Wall Street is positive as the major averages opened higher on Thursday and remained comfortably in the green throughout the session, ending near record highs.</p>\n<p>The Dow jumped 196.67 points or 0.55 percent to finish at 35,950.56, while the NASDAQ climbed 131.48 points or 0.85 percent to close at 15,653.37 and the S&amp;P 500 rose 29.23 points or 0.62 percent to end at 4,725.79. For the holiday-shortened week, the NASDAQ spiked 3.2 percent, the S&amp;P improved 2.3 percent and the Dow gained 1.7 percent.</p>\n<p>Easing concerns about the Omicron variant of the&nbsp;coronavirus&nbsp;contributed to the continued strength on Wall Street, as separate studies have indicated the new strain poses a lower risk of severe disease and hospitalization than the Delta variant.</p>\n<p>Traders were also reacting to a slew of economic data, including a Labor Department report showing first-time claims for U.S. jobless benefits came in flat last week. Also, the Commerce Department said new orders for U.S. manufactured durable goods spiked much more than expected in November.</p>\n<p>Meanwhile, the Commerce Department also noted a continued acceleration in the pace of core consumer price growth last month, and also that new home sales skyrocketed.</p>\n<p>Crude oil futures extended gains to a third straight day amid hopes about outlook for energy demand as concerns about Omicron variant of the coronavirus faded. West Texas Intermediate Crude oil futures for February ended higher by $1.03 or 1.4 percent at $73.79 a barrel.</p>","source":"lsy1626938412129","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Singapore Stock Market Has A Green Light For Friday's Trade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSingapore Stock Market Has A Green Light For Friday's Trade\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-24 08:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.rttnews.com/3251425/singapore-stock-market-has-a-green-light-for-friday-s-trade.aspx><strong>RTTNews</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Singapore stock market has finished higher in three straight sessions, gathering almost 25 points or 0.8 percent along the way. The Straits Times Index now sits just above the 3,095-point plateau ...</p>\n\n<a href=\"https://www.rttnews.com/3251425/singapore-stock-market-has-a-green-light-for-friday-s-trade.aspx\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"STI.SI":"富时新加坡海峡指数"},"source_url":"https://www.rttnews.com/3251425/singapore-stock-market-has-a-green-light-for-friday-s-trade.aspx","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1125729979","content_text":"The Singapore stock market has finished higher in three straight sessions, gathering almost 25 points or 0.8 percent along the way. The Straits Times Index now sits just above the 3,095-point plateau and it may extend its gains on Friday.\nThe global forecast for the Asian markets is upbeat on easing virus concerns, rising crude oil prices and solid economic data. The European and U.S. markets were up and the Asian markets are expected to open in similar fashion.\nThe STI finished modestly higher on Thursday following gains from the financial shares, property stocks and plantations.\nFor the day, the index rose 9.30 points or 0.30 percent to finish at 3,096.81 after trading between 3,090.25 and 3,104.18. Volume was 878.5 million shares worth S$515.8 million. There were 265 gainers and 169 decliners.\nAmong the actives, Ascendas REIT fell 0.34 percent, while CapitaLand Integrated Commercial Trust and Mapletree Commercial Trust both gained 0.51 percent, City Developments jumped 0.76 percent, Comfort DelGro climbed 0.74 percent, Dairy Farm International surged 2.23 percent, DBS Group increased 0.37 percent, Genting Singapore advanced 0.66 percent, Hongkong Land rallied 1.17 percent, Keppel Corp rose 0.39 percent, Mapletree Logistics Trust added 0.54 percent, Oversea-Chinese Banking Corporation collected 0.44 percent, SATS accelerated 1.32 percent, SembCorp Industries shed 0.50 percent, Singapore Airlines spiked 1.45 percent, Singapore Exchange was up 0.11 percent, Singapore Press Holdings lost 0.43 percent, Thai Beverage sank 0.75 percent, Wilmar International soared 1.50 percent and Yangzijiang Shipbuilding, Singapore Technologies Engineering, United Overseas Bank and SingTel were unchanged.\nThe lead from Wall Street is positive as the major averages opened higher on Thursday and remained comfortably in the green throughout the session, ending near record highs.\nThe Dow jumped 196.67 points or 0.55 percent to finish at 35,950.56, while the NASDAQ climbed 131.48 points or 0.85 percent to close at 15,653.37 and the S&P 500 rose 29.23 points or 0.62 percent to end at 4,725.79. For the holiday-shortened week, the NASDAQ spiked 3.2 percent, the S&P improved 2.3 percent and the Dow gained 1.7 percent.\nEasing concerns about the Omicron variant of the coronavirus contributed to the continued strength on Wall Street, as separate studies have indicated the new strain poses a lower risk of severe disease and hospitalization than the Delta variant.\nTraders were also reacting to a slew of economic data, including a Labor Department report showing first-time claims for U.S. jobless benefits came in flat last week. Also, the Commerce Department said new orders for U.S. manufactured durable goods spiked much more than expected in November.\nMeanwhile, the Commerce Department also noted a continued acceleration in the pace of core consumer price growth last month, and also that new home sales skyrocketed.\nCrude oil futures extended gains to a third straight day amid hopes about outlook for energy demand as concerns about Omicron variant of the coronavirus faded. West Texas Intermediate Crude oil futures for February ended higher by $1.03 or 1.4 percent at $73.79 a barrel.","news_type":1},"isVote":1,"tweetType":1,"viewCount":550,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698380328,"gmtCreate":1640304963387,"gmtModify":1640305275063,"author":{"id":"4101174879260110","authorId":"4101174879260110","name":"gil dina","avatar":"https://static.tigerbbs.com/f87f0548663e1e1e6cfee22d9a835013","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like&nbsp;","listText":"Like&nbsp;","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698380328","repostId":"1154370846","repostType":4,"repost":{"id":"1154370846","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1640299823,"share":"https://www.laohu8.com/m/news/1154370846?lang=&edition=full","pubTime":"2021-12-24 06:50","market":"us","language":"en","title":"U.S. authorizes Merck pill as second at-home COVID-19 treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1154370846","media":"Reuters","summary":"Dec 23 (Reuters) - The U.S. on Thursday authorized Merck & Co's(MRK.N)antiviral pill for COVID-19 fo","content":"<p>Dec 23 (Reuters) - The U.S. on Thursday authorized Merck &amp; Co's(MRK.N)antiviral pill for COVID-19 for certain high-risk adult patients, a day after giving a broader go-ahead to a&nbsp;similar but more effective treatment&nbsp;from Pfizer Inc.</p>\n<p>The U.S. Food and Drug Administration said Merck's drug could be used when other authorized treatments are not accessible or clinically appropriate.</p>\n<p>The drug,molnupiravir, was developed with Ridgeback Biotherapeutics and shown to reduce hospitalizations and deaths by around 30% in a clinical trial of high-risk individuals early in the course of the illness.</p>\n<p>The authorization allows use of the drug for mild-to-moderate COVID-19 and along with the&nbsp;Pfizer pill, could be an important tool against the fast-spreading Omicron variant, which is now dominant in the United States.</p>\n<p>Pfizer's drug,Paxlovid, was authorized on Wednesday for people aged 12 and older and has shown to be nearly 90% effective in preventing hospitalizations and deaths in patients at high risk of severe illness, according to trial data.</p>\n<p>The FDA says some patients should avoid Pfizer's two-drug regimen because it includes an older antiviral called ritonavir that is known to have interactions with some other prescription medicines. It is also not recommended for people with severe kidney issues.</p>\n<p>Merck plans to ship hundreds of thousands of treatment courses in coming days and 1 million over the next few weeks. Pfizer plans to ship about 250,000 courses in the next month.</p>\n<p>Availability of other treatments is the first consideration for doctors thinking of prescribing Merck's treatment, according to Patrizia Cavazzoni, the director of FDA's Center for Drug Evaluation and Research.</p>\n<p>The FDA has authorized intravenous treatments, mostly for hospital use, called monoclonal antibodies but availability is limited and efficacy against the Omicron variant is lower.</p>\n<p>FDA official John Farley said during a press briefing that GlaxoSmithKline's&nbsp;and Vir Biotech's&nbsp;antibody drug - which has been shown to work against Omicron - is expected to be in short supply this winter.</p>\n<p>Merck said that its treatment had advantages over the Pfizer pill.</p>\n<p>\"It doesn't require any second drug to boost its efficacy, and you can give it in a variety of special patient populations, including people who have significant issues with liver function or kidney function,\" Nick Kartsonis, Merck's senior vice president of clinical research for vaccines and infectious diseases, told Reuters.</p>\n<p>\"This approval comes at the right time since more COVID-19 treatments are needed to supplement the vaccination effort, especially in light of variants of concern,\" said Cantor Fitzgerald analyst Louise Chen.</p>\n<p>Nearly 62% of people in the United States are fully vaccinated, leaving many Americans unprotected against a wave of Omicron infections. Two doses of the highly successful vaccine from Pfizer Inc and BioNTech SE are only somewhat protective against infection with the Omicron variant while a third dose improves the immune response.</p>\n<p>Merck's and Pfizer's antiviral both work by preventing the virus from replicating. Merck's pill does so by introducing errors into the genetic code of the virus.</p>\n<p>Some of the FDA's experts have said that could lead to more troublesome variants.</p>\n<p>There have also been some safety concerns around the drug because it may affect bone cartilage and growth.</p>\n<p>Due to that reason, Merck's drug is not authorized for use in patients younger than 18, the FDA said. The pill is not recommended for use during pregnancy, the agency added.</p>\n<p>The agency advised that men of reproductive potential use a reliable method of birth control during treatment with molnupiravir, and for at least three months after the final dose.</p>\n<p>The drug is meant to be taken twice a day - four pills each time - for five days, making a full treatment course 40 pills. The treatment was priced at about $700 per course in a deal with the U.S. government for up to 5 million courses.</p>\n<p>The U.S. government has ordered 10 million courses of the Pfizer drug at a price of $530 per course compares to the deal with Merck for as many as 5 million courses of molnupiravir at a price of $700 per course.</p>\n<p>Merck has said molnupiravir, which helps prevent the virus from replicating, should be effective against any variant, including the new Omicron variant.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. authorizes Merck pill as second at-home COVID-19 treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. authorizes Merck pill as second at-home COVID-19 treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-24 06:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Dec 23 (Reuters) - The U.S. on Thursday authorized Merck &amp; Co's(MRK.N)antiviral pill for COVID-19 for certain high-risk adult patients, a day after giving a broader go-ahead to a&nbsp;similar but more effective treatment&nbsp;from Pfizer Inc.</p>\n<p>The U.S. Food and Drug Administration said Merck's drug could be used when other authorized treatments are not accessible or clinically appropriate.</p>\n<p>The drug,molnupiravir, was developed with Ridgeback Biotherapeutics and shown to reduce hospitalizations and deaths by around 30% in a clinical trial of high-risk individuals early in the course of the illness.</p>\n<p>The authorization allows use of the drug for mild-to-moderate COVID-19 and along with the&nbsp;Pfizer pill, could be an important tool against the fast-spreading Omicron variant, which is now dominant in the United States.</p>\n<p>Pfizer's drug,Paxlovid, was authorized on Wednesday for people aged 12 and older and has shown to be nearly 90% effective in preventing hospitalizations and deaths in patients at high risk of severe illness, according to trial data.</p>\n<p>The FDA says some patients should avoid Pfizer's two-drug regimen because it includes an older antiviral called ritonavir that is known to have interactions with some other prescription medicines. It is also not recommended for people with severe kidney issues.</p>\n<p>Merck plans to ship hundreds of thousands of treatment courses in coming days and 1 million over the next few weeks. Pfizer plans to ship about 250,000 courses in the next month.</p>\n<p>Availability of other treatments is the first consideration for doctors thinking of prescribing Merck's treatment, according to Patrizia Cavazzoni, the director of FDA's Center for Drug Evaluation and Research.</p>\n<p>The FDA has authorized intravenous treatments, mostly for hospital use, called monoclonal antibodies but availability is limited and efficacy against the Omicron variant is lower.</p>\n<p>FDA official John Farley said during a press briefing that GlaxoSmithKline's&nbsp;and Vir Biotech's&nbsp;antibody drug - which has been shown to work against Omicron - is expected to be in short supply this winter.</p>\n<p>Merck said that its treatment had advantages over the Pfizer pill.</p>\n<p>\"It doesn't require any second drug to boost its efficacy, and you can give it in a variety of special patient populations, including people who have significant issues with liver function or kidney function,\" Nick Kartsonis, Merck's senior vice president of clinical research for vaccines and infectious diseases, told Reuters.</p>\n<p>\"This approval comes at the right time since more COVID-19 treatments are needed to supplement the vaccination effort, especially in light of variants of concern,\" said Cantor Fitzgerald analyst Louise Chen.</p>\n<p>Nearly 62% of people in the United States are fully vaccinated, leaving many Americans unprotected against a wave of Omicron infections. Two doses of the highly successful vaccine from Pfizer Inc and BioNTech SE are only somewhat protective against infection with the Omicron variant while a third dose improves the immune response.</p>\n<p>Merck's and Pfizer's antiviral both work by preventing the virus from replicating. Merck's pill does so by introducing errors into the genetic code of the virus.</p>\n<p>Some of the FDA's experts have said that could lead to more troublesome variants.</p>\n<p>There have also been some safety concerns around the drug because it may affect bone cartilage and growth.</p>\n<p>Due to that reason, Merck's drug is not authorized for use in patients younger than 18, the FDA said. The pill is not recommended for use during pregnancy, the agency added.</p>\n<p>The agency advised that men of reproductive potential use a reliable method of birth control during treatment with molnupiravir, and for at least three months after the final dose.</p>\n<p>The drug is meant to be taken twice a day - four pills each time - for five days, making a full treatment course 40 pills. The treatment was priced at about $700 per course in a deal with the U.S. government for up to 5 million courses.</p>\n<p>The U.S. government has ordered 10 million courses of the Pfizer drug at a price of $530 per course compares to the deal with Merck for as many as 5 million courses of molnupiravir at a price of $700 per course.</p>\n<p>Merck has said molnupiravir, which helps prevent the virus from replicating, should be effective against any variant, including the new Omicron variant.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1154370846","content_text":"Dec 23 (Reuters) - The U.S. on Thursday authorized Merck & Co's(MRK.N)antiviral pill for COVID-19 for certain high-risk adult patients, a day after giving a broader go-ahead to a similar but more effective treatment from Pfizer Inc.\nThe U.S. Food and Drug Administration said Merck's drug could be used when other authorized treatments are not accessible or clinically appropriate.\nThe drug,molnupiravir, was developed with Ridgeback Biotherapeutics and shown to reduce hospitalizations and deaths by around 30% in a clinical trial of high-risk individuals early in the course of the illness.\nThe authorization allows use of the drug for mild-to-moderate COVID-19 and along with the Pfizer pill, could be an important tool against the fast-spreading Omicron variant, which is now dominant in the United States.\nPfizer's drug,Paxlovid, was authorized on Wednesday for people aged 12 and older and has shown to be nearly 90% effective in preventing hospitalizations and deaths in patients at high risk of severe illness, according to trial data.\nThe FDA says some patients should avoid Pfizer's two-drug regimen because it includes an older antiviral called ritonavir that is known to have interactions with some other prescription medicines. It is also not recommended for people with severe kidney issues.\nMerck plans to ship hundreds of thousands of treatment courses in coming days and 1 million over the next few weeks. Pfizer plans to ship about 250,000 courses in the next month.\nAvailability of other treatments is the first consideration for doctors thinking of prescribing Merck's treatment, according to Patrizia Cavazzoni, the director of FDA's Center for Drug Evaluation and Research.\nThe FDA has authorized intravenous treatments, mostly for hospital use, called monoclonal antibodies but availability is limited and efficacy against the Omicron variant is lower.\nFDA official John Farley said during a press briefing that GlaxoSmithKline's and Vir Biotech's antibody drug - which has been shown to work against Omicron - is expected to be in short supply this winter.\nMerck said that its treatment had advantages over the Pfizer pill.\n\"It doesn't require any second drug to boost its efficacy, and you can give it in a variety of special patient populations, including people who have significant issues with liver function or kidney function,\" Nick Kartsonis, Merck's senior vice president of clinical research for vaccines and infectious diseases, told Reuters.\n\"This approval comes at the right time since more COVID-19 treatments are needed to supplement the vaccination effort, especially in light of variants of concern,\" said Cantor Fitzgerald analyst Louise Chen.\nNearly 62% of people in the United States are fully vaccinated, leaving many Americans unprotected against a wave of Omicron infections. Two doses of the highly successful vaccine from Pfizer Inc and BioNTech SE are only somewhat protective against infection with the Omicron variant while a third dose improves the immune response.\nMerck's and Pfizer's antiviral both work by preventing the virus from replicating. Merck's pill does so by introducing errors into the genetic code of the virus.\nSome of the FDA's experts have said that could lead to more troublesome variants.\nThere have also been some safety concerns around the drug because it may affect bone cartilage and growth.\nDue to that reason, Merck's drug is not authorized for use in patients younger than 18, the FDA said. The pill is not recommended for use during pregnancy, the agency added.\nThe agency advised that men of reproductive potential use a reliable method of birth control during treatment with molnupiravir, and for at least three months after the final dose.\nThe drug is meant to be taken twice a day - four pills each time - for five days, making a full treatment course 40 pills. The treatment was priced at about $700 per course in a deal with the U.S. government for up to 5 million courses.\nThe U.S. government has ordered 10 million courses of the Pfizer drug at a price of $530 per course compares to the deal with Merck for as many as 5 million courses of molnupiravir at a price of $700 per course.\nMerck has said molnupiravir, which helps prevent the virus from replicating, should be effective against any variant, including the new Omicron variant.","news_type":1},"isVote":1,"tweetType":1,"viewCount":472,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698380019,"gmtCreate":1640304910135,"gmtModify":1640305273060,"author":{"id":"4101174879260110","authorId":"4101174879260110","name":"gil dina","avatar":"https://static.tigerbbs.com/f87f0548663e1e1e6cfee22d9a835013","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698380019","repostId":"1102721082","repostType":4,"repost":{"id":"1102721082","pubTimestamp":1640301532,"share":"https://www.laohu8.com/m/news/1102721082?lang=&edition=full","pubTime":"2021-12-24 07:18","market":"fut","language":"en","title":"SEC Spurns Crypto Industry Again, Denying Two Spot-Bitcoin ETFs","url":"https://stock-news.laohu8.com/highlight/detail?id=1102721082","media":"Bloomberg","summary":"Agency passes on a pair of spot ETF filings ahead of Christmas\nValkyrie and Kryptoin’s physically-ba","content":"<ul>\n <li>Agency passes on a pair of spot ETF filings ahead of Christmas</li>\n <li>Valkyrie and Kryptoin’s physically-backed ETF proposals denied</li>\n</ul>\n<p>Regulators rejected a pair of proposals to offer physically-backed Bitcoin exchange-traded funds, handing crypto enthusiasts a proverbial bag of coal ahead of the Christmas holiday.</p>\n<p>The U.S. Securities and Exchange Commission said on Wednesday that the proposals from Valkyrie Investments and Kryptoin failed to meet requirements to prevent fraudulent and manipulative practices that are needed to protect investors. It allowed futures-backed Bitcoin ETFs to be offered in October. The earlier-than-expected decision from the SEC could suggest a 2022 approval for a pure Bitcoin fund may not be in the cards either.</p>\n<p>The deadline for a decision on the two fund proposals was Jan. 7, according to Eric Balchunas, a Bloomberg Intelligence analyst, who likens the early edict as a “Scrooge-jection.”</p>\n<p>The decision comes about a month after after the agency rejected a VanEck application for a spot Bitcoin ETF.</p>\n<p>“The fact that the SEC is disapproving faster than they needed to -- we were optimistic about futures, but we’re not confident in a 2022 approval,” Balchunas said.</p>\n<p>Launching the first spot-Bitcoin ETF remains the holy grail for investment fund providers, who see such products as an entry way into crypto for millions of individual investors. The first Bitcoin futures ETF, ProShares Bitcoin Strategy attracted about $1 billion in investor inflows shortly after its launch.</p>\n<p>The SEC’s decisions on First Trust/Skybridge’s proposed spot-Bitcoin ETF is expected on Jan. 22, to be followed by a decision on Fidelity’s on Jan. 27. The likelihood of those getting approved seems small, according to Bloomberg Intelligence analyst James Seyffart, who joked in a meme depicting the SEC as the Grim Reaper, knocking at First Trust and Skybridge’s door.</p>\n<p><img src=\"https://static.tigerbbs.com/8aa4cc20ddf98dc1efdd260d9947b007\" tg-width=\"667\" tg-height=\"735\" width=\"100%\" height=\"auto\"></p>\n<p>The number of crypto-tracking investment vehicles worldwide more than doubled to 80 from just 35 at the end of 2020, according to Bloomberg Intelligence data. Assets soared to $63 billion, compared to $24 billion at the start of the year.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SEC Spurns Crypto Industry Again, Denying Two Spot-Bitcoin ETFs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSEC Spurns Crypto Industry Again, Denying Two Spot-Bitcoin ETFs\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-24 07:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-12-23/sec-says-bah-humbug-to-spot-bitcoin-etfs-with-latest-rejections?srnd=premium><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Agency passes on a pair of spot ETF filings ahead of Christmas\nValkyrie and Kryptoin’s physically-backed ETF proposals denied\n\nRegulators rejected a pair of proposals to offer physically-backed ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-12-23/sec-says-bah-humbug-to-spot-bitcoin-etfs-with-latest-rejections?srnd=premium\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GBTC":"Grayscale Bitcoin Trust"},"source_url":"https://www.bloomberg.com/news/articles/2021-12-23/sec-says-bah-humbug-to-spot-bitcoin-etfs-with-latest-rejections?srnd=premium","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102721082","content_text":"Agency passes on a pair of spot ETF filings ahead of Christmas\nValkyrie and Kryptoin’s physically-backed ETF proposals denied\n\nRegulators rejected a pair of proposals to offer physically-backed Bitcoin exchange-traded funds, handing crypto enthusiasts a proverbial bag of coal ahead of the Christmas holiday.\nThe U.S. Securities and Exchange Commission said on Wednesday that the proposals from Valkyrie Investments and Kryptoin failed to meet requirements to prevent fraudulent and manipulative practices that are needed to protect investors. It allowed futures-backed Bitcoin ETFs to be offered in October. The earlier-than-expected decision from the SEC could suggest a 2022 approval for a pure Bitcoin fund may not be in the cards either.\nThe deadline for a decision on the two fund proposals was Jan. 7, according to Eric Balchunas, a Bloomberg Intelligence analyst, who likens the early edict as a “Scrooge-jection.”\nThe decision comes about a month after after the agency rejected a VanEck application for a spot Bitcoin ETF.\n“The fact that the SEC is disapproving faster than they needed to -- we were optimistic about futures, but we’re not confident in a 2022 approval,” Balchunas said.\nLaunching the first spot-Bitcoin ETF remains the holy grail for investment fund providers, who see such products as an entry way into crypto for millions of individual investors. The first Bitcoin futures ETF, ProShares Bitcoin Strategy attracted about $1 billion in investor inflows shortly after its launch.\nThe SEC’s decisions on First Trust/Skybridge’s proposed spot-Bitcoin ETF is expected on Jan. 22, to be followed by a decision on Fidelity’s on Jan. 27. The likelihood of those getting approved seems small, according to Bloomberg Intelligence analyst James Seyffart, who joked in a meme depicting the SEC as the Grim Reaper, knocking at First Trust and Skybridge’s door.\n\nThe number of crypto-tracking investment vehicles worldwide more than doubled to 80 from just 35 at the end of 2020, according to Bloomberg Intelligence data. Assets soared to $63 billion, compared to $24 billion at the start of the year.","news_type":1},"isVote":1,"tweetType":1,"viewCount":539,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691275015,"gmtCreate":1640216723473,"gmtModify":1640216723473,"author":{"id":"4101174879260110","authorId":"4101174879260110","name":"gil dina","avatar":"https://static.tigerbbs.com/f87f0548663e1e1e6cfee22d9a835013","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/691275015","repostId":"2193113147","repostType":4,"repost":{"id":"2193113147","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1640213688,"share":"https://www.laohu8.com/m/news/2193113147?lang=&edition=full","pubTime":"2021-12-23 06:54","market":"us","language":"en","title":"Wall St mints strong gains on rosy economic data, encouraging Omicron update","url":"https://stock-news.laohu8.com/highlight/detail?id=2193113147","media":"Reuters","summary":"* Tesla jumps as CEO Musk says he has sold 'enough' stock. * Pfizer rises as oral COVID-19 pill wins approval. Dec 22  - Wall Street's main indexes powered higher on Wednesday in a broad rally after upbeat economic data and hopeful developments about the severity of the Omicron coronavirus variant that is sweeping the world.The S&P 500 gained at least 1% for a second straight session, putting it near record levels, as volatility has ratcheted up in the last month of 2021 following the arrival of","content":"<p>* Consumer confidence index increases in December</p>\n<p>* U.S. Q3 economic growth revised slightly higher</p>\n<p>* Tesla jumps as CEO Musk says he has sold 'enough' stock</p>\n<p>* Pfizer rises as oral COVID-19 pill wins approval</p>\n<p>* Indexes up: Dow 0.74%, S&amp;P 1.02%, Nasdaq 1.18% </p>\n<p>Dec 22 (Reuters) - Wall Street's main indexes powered higher on Wednesday in a broad rally after upbeat economic data and hopeful developments about the severity of the Omicron coronavirus variant that is sweeping the world.</p>\n<p>The S&amp;P 500 gained at least 1% for a second straight session, putting it near record levels, as volatility has ratcheted up in the last month of 2021 following the arrival of Omicron and an otherwise strong year for equities.</p>\n<p>A South African study suggested reduced risks of hospitalization and severe disease in people infected with the Omicron variant versus the Delta one, but World Health Organization officials cautioned that it was too soon to draw firm conclusions.</p>\n<p>“We are still struggling for direction in the face of the Omicron outbreak, but in the past few days ... more and more evidence is building that the strain is potentially less severe than prior strains, specifically Delta, which bodes well for economic momentum in 2022,” said Mike Stritch, chief investment officer at BMO Wealth Management.</p>\n<p>The Dow Jones Industrial Average rose 261.19 points, or 0.74%, to 35,753.89, the S&amp;P 500 gained 47.33 points, or 1.02%, to 4,696.56 and the Nasdaq Composite added 180.81 points, or 1.18%, to 15,521.89.</p>\n<p>All major S&amp;P 500 sectors gained, with the consumer discretionary group up 1.7% and technology up 1.3%.</p>\n<p>Tesla Inc shares rose 7.5%, boosting the S&amp;P 500 and Nasdaq. Tesla Chief Executive Elon Musk said in an interview he has sold \"enough stock\" following several weeks of share sales by the billionaire.</p>\n<p>U.S. consumer confidence improved further in December, suggesting the economy would continue to expand in 2022. The survey from the Conference Board showed more consumers planned to buy a house and big-ticket items such as motor vehicles and major household appliances as well as go on vacation over the next six months.</p>\n<p>Other reports showed U.S. home sales increased for a third straight month in November, and that gross domestic product increased at a 2.3% annualized rate in the July-September quarter, revised up from the 2.1% rate estimated last month.</p>\n<p>In another encouraging development against the pandemic, the United States authorized Pfizer Inc's oral antiviral COVID-19 pill for at-risk people aged 12 and above, making it the first at-home treatment for the coronavirus. Pfizer shares rose 1%.</p>\n<p>The benchmark S&amp;P 500 is now up 25% so far in 2021. Still, the environment for equities could be changing heading into next year as the Federal Reserve is expected to begin raising interest rates in 2022 to rein in inflation.</p>\n<p>The market is \"certainly at an extended level of valuation,\" said Rick Meckler, partner at Cherry Lane Investments in New Vernon, New Jersey. “Next year is a more difficult picture, but if inflation is going to be part of the problem, I think investors will certainly choose stocks over bonds.”</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 3.17-to-1 ratio; on Nasdaq, a 1.65-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 15 new 52-week highs and no new lows; the Nasdaq Composite recorded 35 new highs and 99 new lows.</p>\n<p>About 8.6 billion shares changed hands in U.S. exchanges, below the 11.8 billion daily average over the last 20 sessions.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall St mints strong gains on rosy economic data, encouraging Omicron update</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall St mints strong gains on rosy economic data, encouraging Omicron update\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-23 06:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>* Consumer confidence index increases in December</p>\n<p>* U.S. Q3 economic growth revised slightly higher</p>\n<p>* Tesla jumps as CEO Musk says he has sold 'enough' stock</p>\n<p>* Pfizer rises as oral COVID-19 pill wins approval</p>\n<p>* Indexes up: Dow 0.74%, S&amp;P 1.02%, Nasdaq 1.18% </p>\n<p>Dec 22 (Reuters) - Wall Street's main indexes powered higher on Wednesday in a broad rally after upbeat economic data and hopeful developments about the severity of the Omicron coronavirus variant that is sweeping the world.</p>\n<p>The S&amp;P 500 gained at least 1% for a second straight session, putting it near record levels, as volatility has ratcheted up in the last month of 2021 following the arrival of Omicron and an otherwise strong year for equities.</p>\n<p>A South African study suggested reduced risks of hospitalization and severe disease in people infected with the Omicron variant versus the Delta one, but World Health Organization officials cautioned that it was too soon to draw firm conclusions.</p>\n<p>“We are still struggling for direction in the face of the Omicron outbreak, but in the past few days ... more and more evidence is building that the strain is potentially less severe than prior strains, specifically Delta, which bodes well for economic momentum in 2022,” said Mike Stritch, chief investment officer at BMO Wealth Management.</p>\n<p>The Dow Jones Industrial Average rose 261.19 points, or 0.74%, to 35,753.89, the S&amp;P 500 gained 47.33 points, or 1.02%, to 4,696.56 and the Nasdaq Composite added 180.81 points, or 1.18%, to 15,521.89.</p>\n<p>All major S&amp;P 500 sectors gained, with the consumer discretionary group up 1.7% and technology up 1.3%.</p>\n<p>Tesla Inc shares rose 7.5%, boosting the S&amp;P 500 and Nasdaq. Tesla Chief Executive Elon Musk said in an interview he has sold \"enough stock\" following several weeks of share sales by the billionaire.</p>\n<p>U.S. consumer confidence improved further in December, suggesting the economy would continue to expand in 2022. The survey from the Conference Board showed more consumers planned to buy a house and big-ticket items such as motor vehicles and major household appliances as well as go on vacation over the next six months.</p>\n<p>Other reports showed U.S. home sales increased for a third straight month in November, and that gross domestic product increased at a 2.3% annualized rate in the July-September quarter, revised up from the 2.1% rate estimated last month.</p>\n<p>In another encouraging development against the pandemic, the United States authorized Pfizer Inc's oral antiviral COVID-19 pill for at-risk people aged 12 and above, making it the first at-home treatment for the coronavirus. Pfizer shares rose 1%.</p>\n<p>The benchmark S&amp;P 500 is now up 25% so far in 2021. Still, the environment for equities could be changing heading into next year as the Federal Reserve is expected to begin raising interest rates in 2022 to rein in inflation.</p>\n<p>The market is \"certainly at an extended level of valuation,\" said Rick Meckler, partner at Cherry Lane Investments in New Vernon, New Jersey. “Next year is a more difficult picture, but if inflation is going to be part of the problem, I think investors will certainly choose stocks over bonds.”</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 3.17-to-1 ratio; on Nasdaq, a 1.65-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 15 new 52-week highs and no new lows; the Nasdaq Composite recorded 35 new highs and 99 new lows.</p>\n<p>About 8.6 billion shares changed hands in U.S. exchanges, below the 11.8 billion daily average over the last 20 sessions.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4007":"制药","BK4568":"美国抗疫概念",".IXIC":"NASDAQ Composite",".DJI":"道琼斯","BK4533":"AQR资本管理(全球第二大对冲基金)","TSLA":"特斯拉","COMP":"Compass, Inc.","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193113147","content_text":"* Consumer confidence index increases in December\n* U.S. Q3 economic growth revised slightly higher\n* Tesla jumps as CEO Musk says he has sold 'enough' stock\n* Pfizer rises as oral COVID-19 pill wins approval\n* Indexes up: Dow 0.74%, S&P 1.02%, Nasdaq 1.18% \nDec 22 (Reuters) - Wall Street's main indexes powered higher on Wednesday in a broad rally after upbeat economic data and hopeful developments about the severity of the Omicron coronavirus variant that is sweeping the world.\nThe S&P 500 gained at least 1% for a second straight session, putting it near record levels, as volatility has ratcheted up in the last month of 2021 following the arrival of Omicron and an otherwise strong year for equities.\nA South African study suggested reduced risks of hospitalization and severe disease in people infected with the Omicron variant versus the Delta one, but World Health Organization officials cautioned that it was too soon to draw firm conclusions.\n“We are still struggling for direction in the face of the Omicron outbreak, but in the past few days ... more and more evidence is building that the strain is potentially less severe than prior strains, specifically Delta, which bodes well for economic momentum in 2022,” said Mike Stritch, chief investment officer at BMO Wealth Management.\nThe Dow Jones Industrial Average rose 261.19 points, or 0.74%, to 35,753.89, the S&P 500 gained 47.33 points, or 1.02%, to 4,696.56 and the Nasdaq Composite added 180.81 points, or 1.18%, to 15,521.89.\nAll major S&P 500 sectors gained, with the consumer discretionary group up 1.7% and technology up 1.3%.\nTesla Inc shares rose 7.5%, boosting the S&P 500 and Nasdaq. Tesla Chief Executive Elon Musk said in an interview he has sold \"enough stock\" following several weeks of share sales by the billionaire.\nU.S. consumer confidence improved further in December, suggesting the economy would continue to expand in 2022. The survey from the Conference Board showed more consumers planned to buy a house and big-ticket items such as motor vehicles and major household appliances as well as go on vacation over the next six months.\nOther reports showed U.S. home sales increased for a third straight month in November, and that gross domestic product increased at a 2.3% annualized rate in the July-September quarter, revised up from the 2.1% rate estimated last month.\nIn another encouraging development against the pandemic, the United States authorized Pfizer Inc's oral antiviral COVID-19 pill for at-risk people aged 12 and above, making it the first at-home treatment for the coronavirus. Pfizer shares rose 1%.\nThe benchmark S&P 500 is now up 25% so far in 2021. Still, the environment for equities could be changing heading into next year as the Federal Reserve is expected to begin raising interest rates in 2022 to rein in inflation.\nThe market is \"certainly at an extended level of valuation,\" said Rick Meckler, partner at Cherry Lane Investments in New Vernon, New Jersey. “Next year is a more difficult picture, but if inflation is going to be part of the problem, I think investors will certainly choose stocks over bonds.”\nAdvancing issues outnumbered declining ones on the NYSE by a 3.17-to-1 ratio; on Nasdaq, a 1.65-to-1 ratio favored advancers.\nThe S&P 500 posted 15 new 52-week highs and no new lows; the Nasdaq Composite recorded 35 new highs and 99 new lows.\nAbout 8.6 billion shares changed hands in U.S. exchanges, below the 11.8 billion daily average over the last 20 sessions.","news_type":1},"isVote":1,"tweetType":1,"viewCount":765,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691271645,"gmtCreate":1640216488696,"gmtModify":1640216488696,"author":{"id":"4101174879260110","authorId":"4101174879260110","name":"gil dina","avatar":"https://static.tigerbbs.com/f87f0548663e1e1e6cfee22d9a835013","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Oh no","listText":"Oh no","text":"Oh no","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691271645","repostId":"1104039472","repostType":4,"repost":{"id":"1104039472","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640184691,"share":"https://www.laohu8.com/m/news/1104039472?lang=&edition=full","pubTime":"2021-12-22 22:51","market":"us","language":"en","title":"Biogen shares fell 1.2% in early trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1104039472","media":"Tiger Newspress","summary":"Biogen shares fell 1.2% in early trading.A Japanese health ministry panel said on Wednesday that inc","content":"<p>Biogen&nbsp;shares&nbsp;fell&nbsp;1.2%&nbsp;in&nbsp;early&nbsp;trading.<img src=\"https://static.tigerbbs.com/22ab29bf4110d582a44955c778f3cf48\" tg-width=\"713\" tg-height=\"596\" width=\"100%\" height=\"auto\">A Japanese health ministry panel said on Wednesday that inconsistent trial results made it difficult to determine the efficacy of an Alzheimer's treatment developed by Eisai Co and Biogen Inc.</p>\n<p>Tokyo-based Eisai and its United States partner filed for Japanese regulatory approval just over a year ago for the drug Aduhelm, which was approved in the United States in June.</p>\n<p>In a statement the panel cited inconsistent results from global Phase III trials and a lack of clinical significance in the drug's ability to reduce plaques in the brain. The panel said it would take another look if further data is submitted.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biogen shares fell 1.2% in early trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiogen shares fell 1.2% in early trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-22 22:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Biogen&nbsp;shares&nbsp;fell&nbsp;1.2%&nbsp;in&nbsp;early&nbsp;trading.<img src=\"https://static.tigerbbs.com/22ab29bf4110d582a44955c778f3cf48\" tg-width=\"713\" tg-height=\"596\" width=\"100%\" height=\"auto\">A Japanese health ministry panel said on Wednesday that inconsistent trial results made it difficult to determine the efficacy of an Alzheimer's treatment developed by Eisai Co and Biogen Inc.</p>\n<p>Tokyo-based Eisai and its United States partner filed for Japanese regulatory approval just over a year ago for the drug Aduhelm, which was approved in the United States in June.</p>\n<p>In a statement the panel cited inconsistent results from global Phase III trials and a lack of clinical significance in the drug's ability to reduce plaques in the brain. The panel said it would take another look if further data is submitted.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1104039472","content_text":"Biogen shares fell 1.2% in early trading.A Japanese health ministry panel said on Wednesday that inconsistent trial results made it difficult to determine the efficacy of an Alzheimer's treatment developed by Eisai Co and Biogen Inc.\nTokyo-based Eisai and its United States partner filed for Japanese regulatory approval just over a year ago for the drug Aduhelm, which was approved in the United States in June.\nIn a statement the panel cited inconsistent results from global Phase III trials and a lack of clinical significance in the drug's ability to reduce plaques in the brain. The panel said it would take another look if further data is submitted.","news_type":1},"isVote":1,"tweetType":1,"viewCount":500,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691273446,"gmtCreate":1640216461102,"gmtModify":1640216461191,"author":{"id":"4101174879260110","authorId":"4101174879260110","name":"gil dina","avatar":"https://static.tigerbbs.com/f87f0548663e1e1e6cfee22d9a835013","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691273446","repostId":"2193920361","repostType":4,"repost":{"id":"2193920361","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1640185200,"share":"https://www.laohu8.com/m/news/2193920361?lang=&edition=full","pubTime":"2021-12-22 23:00","market":"us","language":"en","title":"Britain approves Pfizer-BioNTech shot for younger children","url":"https://stock-news.laohu8.com/highlight/detail?id=2193920361","media":"Reuters","summary":"LONDON, Dec 22 (Reuters) - Britain's medicines regulator on Wednesday approved use of the COVID-19 v","content":"<p>LONDON, Dec 22 (Reuters) - Britain's medicines regulator on Wednesday approved use of the COVID-19 vaccine from partners Pfizer and BioNTech for children aged 5 to 11 years, after the watchdog found the shot was safe and effective.</p>\n<p>The country's vaccines committee advised that children in the age group who were in a clinical risk group should be offered the shot.</p>\n<p>The children will receive two 10-microgram doses of the Pfizer-BioNTech vaccine - a third of the adult dose - with an interval of eight weeks between the first and second doses, the Joint Committee on Vaccination and Immunisation said.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Britain approves Pfizer-BioNTech shot for younger children</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBritain approves Pfizer-BioNTech shot for younger children\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-22 23:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>LONDON, Dec 22 (Reuters) - Britain's medicines regulator on Wednesday approved use of the COVID-19 vaccine from partners Pfizer and BioNTech for children aged 5 to 11 years, after the watchdog found the shot was safe and effective.</p>\n<p>The country's vaccines committee advised that children in the age group who were in a clinical risk group should be offered the shot.</p>\n<p>The children will receive two 10-microgram doses of the Pfizer-BioNTech vaccine - a third of the adult dose - with an interval of eight weeks between the first and second doses, the Joint Committee on Vaccination and Immunisation said.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","PFE":"辉瑞","BK4534":"瑞士信贷持仓","BK4568":"美国抗疫概念"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193920361","content_text":"LONDON, Dec 22 (Reuters) - Britain's medicines regulator on Wednesday approved use of the COVID-19 vaccine from partners Pfizer and BioNTech for children aged 5 to 11 years, after the watchdog found the shot was safe and effective.\nThe country's vaccines committee advised that children in the age group who were in a clinical risk group should be offered the shot.\nThe children will receive two 10-microgram doses of the Pfizer-BioNTech vaccine - a third of the adult dose - with an interval of eight weeks between the first and second doses, the Joint Committee on Vaccination and Immunisation said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":845,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691279370,"gmtCreate":1640216333115,"gmtModify":1640216333115,"author":{"id":"4101174879260110","authorId":"4101174879260110","name":"gil dina","avatar":"https://static.tigerbbs.com/f87f0548663e1e1e6cfee22d9a835013","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691279370","repostId":"2193192720","repostType":4,"repost":{"id":"2193192720","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1640185119,"share":"https://www.laohu8.com/m/news/2193192720?lang=&edition=full","pubTime":"2021-12-22 22:58","market":"us","language":"en","title":"Tesla, authorities submit documents for German plant approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2193192720","media":"Reuters","summary":"BERLIN, Dec 22  - Tesla and relevant authorities have submitted all the documents necessary for the approval process for its planned factory near Berlin, the environment ministry of the German state of Brandenburg said on Wednesday.The approval process is still ongoing, the ministry said.Tesla could not be immediately reached for comment.Due to environmental resistance and red tape, it remained unclear when the first vehicles will roll off the production line at the site. Brandenburg premier Die","content":"<p>BERLIN, Dec 22 (Reuters) - Tesla and relevant authorities have submitted all the documents necessary for the approval process for its planned factory near Berlin, the environment ministry of the German state of Brandenburg said on Wednesday.</p>\n<p>The approval process is still ongoing, the ministry said.</p>\n<p>Tesla could not be immediately reached for comment.</p>\n<p>Due to environmental resistance and red tape, it remained unclear when the first vehicles will roll off the production line at the site. Brandenburg premier Dietmar Woidke had recently suggested a decision might come in early 2022.</p>\n<p>Tesla has repeatedly had to push back the expected opening of the factory and Chief Executive Elon Musk has regularly travelled to Germany to check on the plant's progress, criticising German bureaucracy for slowing down construction.</p>\n<p>Since Tesla expanded its original proposal to include a battery factory, the construction plans had to undergo a renewed process of public consultation which ended on Nov. 22.</p>\n<p>The response to all objections raised in that consultation is a prerequisite for a final building permit.</p>\n<p>Currently, Tesla is only working on the factory on the basis of preliminary building permits.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla, authorities submit documents for German plant approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla, authorities submit documents for German plant approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-22 22:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BERLIN, Dec 22 (Reuters) - Tesla and relevant authorities have submitted all the documents necessary for the approval process for its planned factory near Berlin, the environment ministry of the German state of Brandenburg said on Wednesday.</p>\n<p>The approval process is still ongoing, the ministry said.</p>\n<p>Tesla could not be immediately reached for comment.</p>\n<p>Due to environmental resistance and red tape, it remained unclear when the first vehicles will roll off the production line at the site. Brandenburg premier Dietmar Woidke had recently suggested a decision might come in early 2022.</p>\n<p>Tesla has repeatedly had to push back the expected opening of the factory and Chief Executive Elon Musk has regularly travelled to Germany to check on the plant's progress, criticising German bureaucracy for slowing down construction.</p>\n<p>Since Tesla expanded its original proposal to include a battery factory, the construction plans had to undergo a renewed process of public consultation which ended on Nov. 22.</p>\n<p>The response to all objections raised in that consultation is a prerequisite for a final building permit.</p>\n<p>Currently, Tesla is only working on the factory on the basis of preliminary building permits.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4099":"汽车制造商","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓","BK4534":"瑞士信贷持仓","BK4527":"明星科技股","BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4555":"新能源车","TSLA":"特斯拉"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193192720","content_text":"BERLIN, Dec 22 (Reuters) - Tesla and relevant authorities have submitted all the documents necessary for the approval process for its planned factory near Berlin, the environment ministry of the German state of Brandenburg said on Wednesday.\nThe approval process is still ongoing, the ministry said.\nTesla could not be immediately reached for comment.\nDue to environmental resistance and red tape, it remained unclear when the first vehicles will roll off the production line at the site. Brandenburg premier Dietmar Woidke had recently suggested a decision might come in early 2022.\nTesla has repeatedly had to push back the expected opening of the factory and Chief Executive Elon Musk has regularly travelled to Germany to check on the plant's progress, criticising German bureaucracy for slowing down construction.\nSince Tesla expanded its original proposal to include a battery factory, the construction plans had to undergo a renewed process of public consultation which ended on Nov. 22.\nThe response to all objections raised in that consultation is a prerequisite for a final building permit.\nCurrently, Tesla is only working on the factory on the basis of preliminary building permits.","news_type":1},"isVote":1,"tweetType":1,"viewCount":714,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":698389672,"gmtCreate":1640305061243,"gmtModify":1640305284888,"author":{"id":"4101174879260110","authorId":"4101174879260110","name":"gil dina","avatar":"https://static.tigerbbs.com/f87f0548663e1e1e6cfee22d9a835013","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/698389672","repostId":"1125729979","repostType":4,"repost":{"id":"1125729979","pubTimestamp":1640304436,"share":"https://www.laohu8.com/m/news/1125729979?lang=&edition=full","pubTime":"2021-12-24 08:07","market":"sg","language":"en","title":"Singapore Stock Market Has A Green Light For Friday's Trade","url":"https://stock-news.laohu8.com/highlight/detail?id=1125729979","media":"RTTNews","summary":"The Singapore stock market has finished higher in three straight sessions, gathering almost 25 point","content":"<p>The Singapore stock market has finished higher in three straight sessions, gathering almost 25 points or 0.8 percent along the way. The Straits Times Index now sits just above the 3,095-point plateau and it may extend its gains on Friday.</p>\n<p>The global forecast for the Asian&nbsp;markets&nbsp;is upbeat on easing virus concerns, rising crude oil prices and solid economic data. The European and U.S. markets were up and the Asian markets are expected to open in similar fashion.</p>\n<p>The STI finished modestly higher on Thursday following gains from the financial shares, property stocks and plantations.</p>\n<p>For the day, the index rose 9.30 points or 0.30 percent to finish at 3,096.81 after trading between 3,090.25 and 3,104.18. Volume was 878.5 million shares worth S$515.8 million. There were 265 gainers and 169 decliners.</p>\n<p>Among the actives, Ascendas REIT fell 0.34 percent, while CapitaLand Integrated Commercial Trust and Mapletree Commercial Trust both gained 0.51 percent, City Developments jumped 0.76 percent, Comfort DelGro climbed 0.74 percent, Dairy Farm International surged 2.23 percent, DBS Group increased 0.37 percent, Genting Singapore advanced 0.66 percent, Hongkong Land rallied 1.17 percent, Keppel Corp rose 0.39 percent, Mapletree Logistics Trust added 0.54 percent, Oversea-Chinese Banking Corporation collected 0.44 percent, SATS accelerated 1.32 percent, SembCorp Industries shed 0.50 percent, Singapore Airlines spiked 1.45 percent, Singapore Exchange was up 0.11 percent, Singapore Press Holdings lost 0.43 percent, Thai Beverage sank 0.75 percent, Wilmar International soared 1.50 percent and Yangzijiang Shipbuilding, Singapore Technologies Engineering, United Overseas Bank and SingTel were unchanged.</p>\n<p>The lead from Wall Street is positive as the major averages opened higher on Thursday and remained comfortably in the green throughout the session, ending near record highs.</p>\n<p>The Dow jumped 196.67 points or 0.55 percent to finish at 35,950.56, while the NASDAQ climbed 131.48 points or 0.85 percent to close at 15,653.37 and the S&amp;P 500 rose 29.23 points or 0.62 percent to end at 4,725.79. For the holiday-shortened week, the NASDAQ spiked 3.2 percent, the S&amp;P improved 2.3 percent and the Dow gained 1.7 percent.</p>\n<p>Easing concerns about the Omicron variant of the&nbsp;coronavirus&nbsp;contributed to the continued strength on Wall Street, as separate studies have indicated the new strain poses a lower risk of severe disease and hospitalization than the Delta variant.</p>\n<p>Traders were also reacting to a slew of economic data, including a Labor Department report showing first-time claims for U.S. jobless benefits came in flat last week. Also, the Commerce Department said new orders for U.S. manufactured durable goods spiked much more than expected in November.</p>\n<p>Meanwhile, the Commerce Department also noted a continued acceleration in the pace of core consumer price growth last month, and also that new home sales skyrocketed.</p>\n<p>Crude oil futures extended gains to a third straight day amid hopes about outlook for energy demand as concerns about Omicron variant of the coronavirus faded. West Texas Intermediate Crude oil futures for February ended higher by $1.03 or 1.4 percent at $73.79 a barrel.</p>","source":"lsy1626938412129","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Singapore Stock Market Has A Green Light For Friday's Trade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSingapore Stock Market Has A Green Light For Friday's Trade\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-24 08:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.rttnews.com/3251425/singapore-stock-market-has-a-green-light-for-friday-s-trade.aspx><strong>RTTNews</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Singapore stock market has finished higher in three straight sessions, gathering almost 25 points or 0.8 percent along the way. The Straits Times Index now sits just above the 3,095-point plateau ...</p>\n\n<a href=\"https://www.rttnews.com/3251425/singapore-stock-market-has-a-green-light-for-friday-s-trade.aspx\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"STI.SI":"富时新加坡海峡指数"},"source_url":"https://www.rttnews.com/3251425/singapore-stock-market-has-a-green-light-for-friday-s-trade.aspx","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1125729979","content_text":"The Singapore stock market has finished higher in three straight sessions, gathering almost 25 points or 0.8 percent along the way. The Straits Times Index now sits just above the 3,095-point plateau and it may extend its gains on Friday.\nThe global forecast for the Asian markets is upbeat on easing virus concerns, rising crude oil prices and solid economic data. The European and U.S. markets were up and the Asian markets are expected to open in similar fashion.\nThe STI finished modestly higher on Thursday following gains from the financial shares, property stocks and plantations.\nFor the day, the index rose 9.30 points or 0.30 percent to finish at 3,096.81 after trading between 3,090.25 and 3,104.18. Volume was 878.5 million shares worth S$515.8 million. There were 265 gainers and 169 decliners.\nAmong the actives, Ascendas REIT fell 0.34 percent, while CapitaLand Integrated Commercial Trust and Mapletree Commercial Trust both gained 0.51 percent, City Developments jumped 0.76 percent, Comfort DelGro climbed 0.74 percent, Dairy Farm International surged 2.23 percent, DBS Group increased 0.37 percent, Genting Singapore advanced 0.66 percent, Hongkong Land rallied 1.17 percent, Keppel Corp rose 0.39 percent, Mapletree Logistics Trust added 0.54 percent, Oversea-Chinese Banking Corporation collected 0.44 percent, SATS accelerated 1.32 percent, SembCorp Industries shed 0.50 percent, Singapore Airlines spiked 1.45 percent, Singapore Exchange was up 0.11 percent, Singapore Press Holdings lost 0.43 percent, Thai Beverage sank 0.75 percent, Wilmar International soared 1.50 percent and Yangzijiang Shipbuilding, Singapore Technologies Engineering, United Overseas Bank and SingTel were unchanged.\nThe lead from Wall Street is positive as the major averages opened higher on Thursday and remained comfortably in the green throughout the session, ending near record highs.\nThe Dow jumped 196.67 points or 0.55 percent to finish at 35,950.56, while the NASDAQ climbed 131.48 points or 0.85 percent to close at 15,653.37 and the S&P 500 rose 29.23 points or 0.62 percent to end at 4,725.79. For the holiday-shortened week, the NASDAQ spiked 3.2 percent, the S&P improved 2.3 percent and the Dow gained 1.7 percent.\nEasing concerns about the Omicron variant of the coronavirus contributed to the continued strength on Wall Street, as separate studies have indicated the new strain poses a lower risk of severe disease and hospitalization than the Delta variant.\nTraders were also reacting to a slew of economic data, including a Labor Department report showing first-time claims for U.S. jobless benefits came in flat last week. Also, the Commerce Department said new orders for U.S. manufactured durable goods spiked much more than expected in November.\nMeanwhile, the Commerce Department also noted a continued acceleration in the pace of core consumer price growth last month, and also that new home sales skyrocketed.\nCrude oil futures extended gains to a third straight day amid hopes about outlook for energy demand as concerns about Omicron variant of the coronavirus faded. West Texas Intermediate Crude oil futures for February ended higher by $1.03 or 1.4 percent at $73.79 a barrel.","news_type":1},"isVote":1,"tweetType":1,"viewCount":550,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691275015,"gmtCreate":1640216723473,"gmtModify":1640216723473,"author":{"id":"4101174879260110","authorId":"4101174879260110","name":"gil dina","avatar":"https://static.tigerbbs.com/f87f0548663e1e1e6cfee22d9a835013","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/691275015","repostId":"2193113147","repostType":4,"repost":{"id":"2193113147","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1640213688,"share":"https://www.laohu8.com/m/news/2193113147?lang=&edition=full","pubTime":"2021-12-23 06:54","market":"us","language":"en","title":"Wall St mints strong gains on rosy economic data, encouraging Omicron update","url":"https://stock-news.laohu8.com/highlight/detail?id=2193113147","media":"Reuters","summary":"* Tesla jumps as CEO Musk says he has sold 'enough' stock. * Pfizer rises as oral COVID-19 pill wins approval. Dec 22  - Wall Street's main indexes powered higher on Wednesday in a broad rally after upbeat economic data and hopeful developments about the severity of the Omicron coronavirus variant that is sweeping the world.The S&P 500 gained at least 1% for a second straight session, putting it near record levels, as volatility has ratcheted up in the last month of 2021 following the arrival of","content":"<p>* Consumer confidence index increases in December</p>\n<p>* U.S. Q3 economic growth revised slightly higher</p>\n<p>* Tesla jumps as CEO Musk says he has sold 'enough' stock</p>\n<p>* Pfizer rises as oral COVID-19 pill wins approval</p>\n<p>* Indexes up: Dow 0.74%, S&amp;P 1.02%, Nasdaq 1.18% </p>\n<p>Dec 22 (Reuters) - Wall Street's main indexes powered higher on Wednesday in a broad rally after upbeat economic data and hopeful developments about the severity of the Omicron coronavirus variant that is sweeping the world.</p>\n<p>The S&amp;P 500 gained at least 1% for a second straight session, putting it near record levels, as volatility has ratcheted up in the last month of 2021 following the arrival of Omicron and an otherwise strong year for equities.</p>\n<p>A South African study suggested reduced risks of hospitalization and severe disease in people infected with the Omicron variant versus the Delta one, but World Health Organization officials cautioned that it was too soon to draw firm conclusions.</p>\n<p>“We are still struggling for direction in the face of the Omicron outbreak, but in the past few days ... more and more evidence is building that the strain is potentially less severe than prior strains, specifically Delta, which bodes well for economic momentum in 2022,” said Mike Stritch, chief investment officer at BMO Wealth Management.</p>\n<p>The Dow Jones Industrial Average rose 261.19 points, or 0.74%, to 35,753.89, the S&amp;P 500 gained 47.33 points, or 1.02%, to 4,696.56 and the Nasdaq Composite added 180.81 points, or 1.18%, to 15,521.89.</p>\n<p>All major S&amp;P 500 sectors gained, with the consumer discretionary group up 1.7% and technology up 1.3%.</p>\n<p>Tesla Inc shares rose 7.5%, boosting the S&amp;P 500 and Nasdaq. Tesla Chief Executive Elon Musk said in an interview he has sold \"enough stock\" following several weeks of share sales by the billionaire.</p>\n<p>U.S. consumer confidence improved further in December, suggesting the economy would continue to expand in 2022. The survey from the Conference Board showed more consumers planned to buy a house and big-ticket items such as motor vehicles and major household appliances as well as go on vacation over the next six months.</p>\n<p>Other reports showed U.S. home sales increased for a third straight month in November, and that gross domestic product increased at a 2.3% annualized rate in the July-September quarter, revised up from the 2.1% rate estimated last month.</p>\n<p>In another encouraging development against the pandemic, the United States authorized Pfizer Inc's oral antiviral COVID-19 pill for at-risk people aged 12 and above, making it the first at-home treatment for the coronavirus. Pfizer shares rose 1%.</p>\n<p>The benchmark S&amp;P 500 is now up 25% so far in 2021. Still, the environment for equities could be changing heading into next year as the Federal Reserve is expected to begin raising interest rates in 2022 to rein in inflation.</p>\n<p>The market is \"certainly at an extended level of valuation,\" said Rick Meckler, partner at Cherry Lane Investments in New Vernon, New Jersey. “Next year is a more difficult picture, but if inflation is going to be part of the problem, I think investors will certainly choose stocks over bonds.”</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 3.17-to-1 ratio; on Nasdaq, a 1.65-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 15 new 52-week highs and no new lows; the Nasdaq Composite recorded 35 new highs and 99 new lows.</p>\n<p>About 8.6 billion shares changed hands in U.S. exchanges, below the 11.8 billion daily average over the last 20 sessions.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall St mints strong gains on rosy economic data, encouraging Omicron update</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall St mints strong gains on rosy economic data, encouraging Omicron update\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-23 06:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>* Consumer confidence index increases in December</p>\n<p>* U.S. Q3 economic growth revised slightly higher</p>\n<p>* Tesla jumps as CEO Musk says he has sold 'enough' stock</p>\n<p>* Pfizer rises as oral COVID-19 pill wins approval</p>\n<p>* Indexes up: Dow 0.74%, S&amp;P 1.02%, Nasdaq 1.18% </p>\n<p>Dec 22 (Reuters) - Wall Street's main indexes powered higher on Wednesday in a broad rally after upbeat economic data and hopeful developments about the severity of the Omicron coronavirus variant that is sweeping the world.</p>\n<p>The S&amp;P 500 gained at least 1% for a second straight session, putting it near record levels, as volatility has ratcheted up in the last month of 2021 following the arrival of Omicron and an otherwise strong year for equities.</p>\n<p>A South African study suggested reduced risks of hospitalization and severe disease in people infected with the Omicron variant versus the Delta one, but World Health Organization officials cautioned that it was too soon to draw firm conclusions.</p>\n<p>“We are still struggling for direction in the face of the Omicron outbreak, but in the past few days ... more and more evidence is building that the strain is potentially less severe than prior strains, specifically Delta, which bodes well for economic momentum in 2022,” said Mike Stritch, chief investment officer at BMO Wealth Management.</p>\n<p>The Dow Jones Industrial Average rose 261.19 points, or 0.74%, to 35,753.89, the S&amp;P 500 gained 47.33 points, or 1.02%, to 4,696.56 and the Nasdaq Composite added 180.81 points, or 1.18%, to 15,521.89.</p>\n<p>All major S&amp;P 500 sectors gained, with the consumer discretionary group up 1.7% and technology up 1.3%.</p>\n<p>Tesla Inc shares rose 7.5%, boosting the S&amp;P 500 and Nasdaq. Tesla Chief Executive Elon Musk said in an interview he has sold \"enough stock\" following several weeks of share sales by the billionaire.</p>\n<p>U.S. consumer confidence improved further in December, suggesting the economy would continue to expand in 2022. The survey from the Conference Board showed more consumers planned to buy a house and big-ticket items such as motor vehicles and major household appliances as well as go on vacation over the next six months.</p>\n<p>Other reports showed U.S. home sales increased for a third straight month in November, and that gross domestic product increased at a 2.3% annualized rate in the July-September quarter, revised up from the 2.1% rate estimated last month.</p>\n<p>In another encouraging development against the pandemic, the United States authorized Pfizer Inc's oral antiviral COVID-19 pill for at-risk people aged 12 and above, making it the first at-home treatment for the coronavirus. Pfizer shares rose 1%.</p>\n<p>The benchmark S&amp;P 500 is now up 25% so far in 2021. Still, the environment for equities could be changing heading into next year as the Federal Reserve is expected to begin raising interest rates in 2022 to rein in inflation.</p>\n<p>The market is \"certainly at an extended level of valuation,\" said Rick Meckler, partner at Cherry Lane Investments in New Vernon, New Jersey. “Next year is a more difficult picture, but if inflation is going to be part of the problem, I think investors will certainly choose stocks over bonds.”</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 3.17-to-1 ratio; on Nasdaq, a 1.65-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 15 new 52-week highs and no new lows; the Nasdaq Composite recorded 35 new highs and 99 new lows.</p>\n<p>About 8.6 billion shares changed hands in U.S. exchanges, below the 11.8 billion daily average over the last 20 sessions.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4007":"制药","BK4568":"美国抗疫概念",".IXIC":"NASDAQ Composite",".DJI":"道琼斯","BK4533":"AQR资本管理(全球第二大对冲基金)","TSLA":"特斯拉","COMP":"Compass, Inc.","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193113147","content_text":"* Consumer confidence index increases in December\n* U.S. Q3 economic growth revised slightly higher\n* Tesla jumps as CEO Musk says he has sold 'enough' stock\n* Pfizer rises as oral COVID-19 pill wins approval\n* Indexes up: Dow 0.74%, S&P 1.02%, Nasdaq 1.18% \nDec 22 (Reuters) - Wall Street's main indexes powered higher on Wednesday in a broad rally after upbeat economic data and hopeful developments about the severity of the Omicron coronavirus variant that is sweeping the world.\nThe S&P 500 gained at least 1% for a second straight session, putting it near record levels, as volatility has ratcheted up in the last month of 2021 following the arrival of Omicron and an otherwise strong year for equities.\nA South African study suggested reduced risks of hospitalization and severe disease in people infected with the Omicron variant versus the Delta one, but World Health Organization officials cautioned that it was too soon to draw firm conclusions.\n“We are still struggling for direction in the face of the Omicron outbreak, but in the past few days ... more and more evidence is building that the strain is potentially less severe than prior strains, specifically Delta, which bodes well for economic momentum in 2022,” said Mike Stritch, chief investment officer at BMO Wealth Management.\nThe Dow Jones Industrial Average rose 261.19 points, or 0.74%, to 35,753.89, the S&P 500 gained 47.33 points, or 1.02%, to 4,696.56 and the Nasdaq Composite added 180.81 points, or 1.18%, to 15,521.89.\nAll major S&P 500 sectors gained, with the consumer discretionary group up 1.7% and technology up 1.3%.\nTesla Inc shares rose 7.5%, boosting the S&P 500 and Nasdaq. Tesla Chief Executive Elon Musk said in an interview he has sold \"enough stock\" following several weeks of share sales by the billionaire.\nU.S. consumer confidence improved further in December, suggesting the economy would continue to expand in 2022. The survey from the Conference Board showed more consumers planned to buy a house and big-ticket items such as motor vehicles and major household appliances as well as go on vacation over the next six months.\nOther reports showed U.S. home sales increased for a third straight month in November, and that gross domestic product increased at a 2.3% annualized rate in the July-September quarter, revised up from the 2.1% rate estimated last month.\nIn another encouraging development against the pandemic, the United States authorized Pfizer Inc's oral antiviral COVID-19 pill for at-risk people aged 12 and above, making it the first at-home treatment for the coronavirus. Pfizer shares rose 1%.\nThe benchmark S&P 500 is now up 25% so far in 2021. Still, the environment for equities could be changing heading into next year as the Federal Reserve is expected to begin raising interest rates in 2022 to rein in inflation.\nThe market is \"certainly at an extended level of valuation,\" said Rick Meckler, partner at Cherry Lane Investments in New Vernon, New Jersey. “Next year is a more difficult picture, but if inflation is going to be part of the problem, I think investors will certainly choose stocks over bonds.”\nAdvancing issues outnumbered declining ones on the NYSE by a 3.17-to-1 ratio; on Nasdaq, a 1.65-to-1 ratio favored advancers.\nThe S&P 500 posted 15 new 52-week highs and no new lows; the Nasdaq Composite recorded 35 new highs and 99 new lows.\nAbout 8.6 billion shares changed hands in U.S. exchanges, below the 11.8 billion daily average over the last 20 sessions.","news_type":1},"isVote":1,"tweetType":1,"viewCount":765,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698380328,"gmtCreate":1640304963387,"gmtModify":1640305275063,"author":{"id":"4101174879260110","authorId":"4101174879260110","name":"gil dina","avatar":"https://static.tigerbbs.com/f87f0548663e1e1e6cfee22d9a835013","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like&nbsp;","listText":"Like&nbsp;","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698380328","repostId":"1154370846","repostType":4,"repost":{"id":"1154370846","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1640299823,"share":"https://www.laohu8.com/m/news/1154370846?lang=&edition=full","pubTime":"2021-12-24 06:50","market":"us","language":"en","title":"U.S. authorizes Merck pill as second at-home COVID-19 treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1154370846","media":"Reuters","summary":"Dec 23 (Reuters) - The U.S. on Thursday authorized Merck & Co's(MRK.N)antiviral pill for COVID-19 fo","content":"<p>Dec 23 (Reuters) - The U.S. on Thursday authorized Merck &amp; Co's(MRK.N)antiviral pill for COVID-19 for certain high-risk adult patients, a day after giving a broader go-ahead to a&nbsp;similar but more effective treatment&nbsp;from Pfizer Inc.</p>\n<p>The U.S. Food and Drug Administration said Merck's drug could be used when other authorized treatments are not accessible or clinically appropriate.</p>\n<p>The drug,molnupiravir, was developed with Ridgeback Biotherapeutics and shown to reduce hospitalizations and deaths by around 30% in a clinical trial of high-risk individuals early in the course of the illness.</p>\n<p>The authorization allows use of the drug for mild-to-moderate COVID-19 and along with the&nbsp;Pfizer pill, could be an important tool against the fast-spreading Omicron variant, which is now dominant in the United States.</p>\n<p>Pfizer's drug,Paxlovid, was authorized on Wednesday for people aged 12 and older and has shown to be nearly 90% effective in preventing hospitalizations and deaths in patients at high risk of severe illness, according to trial data.</p>\n<p>The FDA says some patients should avoid Pfizer's two-drug regimen because it includes an older antiviral called ritonavir that is known to have interactions with some other prescription medicines. It is also not recommended for people with severe kidney issues.</p>\n<p>Merck plans to ship hundreds of thousands of treatment courses in coming days and 1 million over the next few weeks. Pfizer plans to ship about 250,000 courses in the next month.</p>\n<p>Availability of other treatments is the first consideration for doctors thinking of prescribing Merck's treatment, according to Patrizia Cavazzoni, the director of FDA's Center for Drug Evaluation and Research.</p>\n<p>The FDA has authorized intravenous treatments, mostly for hospital use, called monoclonal antibodies but availability is limited and efficacy against the Omicron variant is lower.</p>\n<p>FDA official John Farley said during a press briefing that GlaxoSmithKline's&nbsp;and Vir Biotech's&nbsp;antibody drug - which has been shown to work against Omicron - is expected to be in short supply this winter.</p>\n<p>Merck said that its treatment had advantages over the Pfizer pill.</p>\n<p>\"It doesn't require any second drug to boost its efficacy, and you can give it in a variety of special patient populations, including people who have significant issues with liver function or kidney function,\" Nick Kartsonis, Merck's senior vice president of clinical research for vaccines and infectious diseases, told Reuters.</p>\n<p>\"This approval comes at the right time since more COVID-19 treatments are needed to supplement the vaccination effort, especially in light of variants of concern,\" said Cantor Fitzgerald analyst Louise Chen.</p>\n<p>Nearly 62% of people in the United States are fully vaccinated, leaving many Americans unprotected against a wave of Omicron infections. Two doses of the highly successful vaccine from Pfizer Inc and BioNTech SE are only somewhat protective against infection with the Omicron variant while a third dose improves the immune response.</p>\n<p>Merck's and Pfizer's antiviral both work by preventing the virus from replicating. Merck's pill does so by introducing errors into the genetic code of the virus.</p>\n<p>Some of the FDA's experts have said that could lead to more troublesome variants.</p>\n<p>There have also been some safety concerns around the drug because it may affect bone cartilage and growth.</p>\n<p>Due to that reason, Merck's drug is not authorized for use in patients younger than 18, the FDA said. The pill is not recommended for use during pregnancy, the agency added.</p>\n<p>The agency advised that men of reproductive potential use a reliable method of birth control during treatment with molnupiravir, and for at least three months after the final dose.</p>\n<p>The drug is meant to be taken twice a day - four pills each time - for five days, making a full treatment course 40 pills. The treatment was priced at about $700 per course in a deal with the U.S. government for up to 5 million courses.</p>\n<p>The U.S. government has ordered 10 million courses of the Pfizer drug at a price of $530 per course compares to the deal with Merck for as many as 5 million courses of molnupiravir at a price of $700 per course.</p>\n<p>Merck has said molnupiravir, which helps prevent the virus from replicating, should be effective against any variant, including the new Omicron variant.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. authorizes Merck pill as second at-home COVID-19 treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. authorizes Merck pill as second at-home COVID-19 treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-24 06:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Dec 23 (Reuters) - The U.S. on Thursday authorized Merck &amp; Co's(MRK.N)antiviral pill for COVID-19 for certain high-risk adult patients, a day after giving a broader go-ahead to a&nbsp;similar but more effective treatment&nbsp;from Pfizer Inc.</p>\n<p>The U.S. Food and Drug Administration said Merck's drug could be used when other authorized treatments are not accessible or clinically appropriate.</p>\n<p>The drug,molnupiravir, was developed with Ridgeback Biotherapeutics and shown to reduce hospitalizations and deaths by around 30% in a clinical trial of high-risk individuals early in the course of the illness.</p>\n<p>The authorization allows use of the drug for mild-to-moderate COVID-19 and along with the&nbsp;Pfizer pill, could be an important tool against the fast-spreading Omicron variant, which is now dominant in the United States.</p>\n<p>Pfizer's drug,Paxlovid, was authorized on Wednesday for people aged 12 and older and has shown to be nearly 90% effective in preventing hospitalizations and deaths in patients at high risk of severe illness, according to trial data.</p>\n<p>The FDA says some patients should avoid Pfizer's two-drug regimen because it includes an older antiviral called ritonavir that is known to have interactions with some other prescription medicines. It is also not recommended for people with severe kidney issues.</p>\n<p>Merck plans to ship hundreds of thousands of treatment courses in coming days and 1 million over the next few weeks. Pfizer plans to ship about 250,000 courses in the next month.</p>\n<p>Availability of other treatments is the first consideration for doctors thinking of prescribing Merck's treatment, according to Patrizia Cavazzoni, the director of FDA's Center for Drug Evaluation and Research.</p>\n<p>The FDA has authorized intravenous treatments, mostly for hospital use, called monoclonal antibodies but availability is limited and efficacy against the Omicron variant is lower.</p>\n<p>FDA official John Farley said during a press briefing that GlaxoSmithKline's&nbsp;and Vir Biotech's&nbsp;antibody drug - which has been shown to work against Omicron - is expected to be in short supply this winter.</p>\n<p>Merck said that its treatment had advantages over the Pfizer pill.</p>\n<p>\"It doesn't require any second drug to boost its efficacy, and you can give it in a variety of special patient populations, including people who have significant issues with liver function or kidney function,\" Nick Kartsonis, Merck's senior vice president of clinical research for vaccines and infectious diseases, told Reuters.</p>\n<p>\"This approval comes at the right time since more COVID-19 treatments are needed to supplement the vaccination effort, especially in light of variants of concern,\" said Cantor Fitzgerald analyst Louise Chen.</p>\n<p>Nearly 62% of people in the United States are fully vaccinated, leaving many Americans unprotected against a wave of Omicron infections. Two doses of the highly successful vaccine from Pfizer Inc and BioNTech SE are only somewhat protective against infection with the Omicron variant while a third dose improves the immune response.</p>\n<p>Merck's and Pfizer's antiviral both work by preventing the virus from replicating. Merck's pill does so by introducing errors into the genetic code of the virus.</p>\n<p>Some of the FDA's experts have said that could lead to more troublesome variants.</p>\n<p>There have also been some safety concerns around the drug because it may affect bone cartilage and growth.</p>\n<p>Due to that reason, Merck's drug is not authorized for use in patients younger than 18, the FDA said. The pill is not recommended for use during pregnancy, the agency added.</p>\n<p>The agency advised that men of reproductive potential use a reliable method of birth control during treatment with molnupiravir, and for at least three months after the final dose.</p>\n<p>The drug is meant to be taken twice a day - four pills each time - for five days, making a full treatment course 40 pills. The treatment was priced at about $700 per course in a deal with the U.S. government for up to 5 million courses.</p>\n<p>The U.S. government has ordered 10 million courses of the Pfizer drug at a price of $530 per course compares to the deal with Merck for as many as 5 million courses of molnupiravir at a price of $700 per course.</p>\n<p>Merck has said molnupiravir, which helps prevent the virus from replicating, should be effective against any variant, including the new Omicron variant.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1154370846","content_text":"Dec 23 (Reuters) - The U.S. on Thursday authorized Merck & Co's(MRK.N)antiviral pill for COVID-19 for certain high-risk adult patients, a day after giving a broader go-ahead to a similar but more effective treatment from Pfizer Inc.\nThe U.S. Food and Drug Administration said Merck's drug could be used when other authorized treatments are not accessible or clinically appropriate.\nThe drug,molnupiravir, was developed with Ridgeback Biotherapeutics and shown to reduce hospitalizations and deaths by around 30% in a clinical trial of high-risk individuals early in the course of the illness.\nThe authorization allows use of the drug for mild-to-moderate COVID-19 and along with the Pfizer pill, could be an important tool against the fast-spreading Omicron variant, which is now dominant in the United States.\nPfizer's drug,Paxlovid, was authorized on Wednesday for people aged 12 and older and has shown to be nearly 90% effective in preventing hospitalizations and deaths in patients at high risk of severe illness, according to trial data.\nThe FDA says some patients should avoid Pfizer's two-drug regimen because it includes an older antiviral called ritonavir that is known to have interactions with some other prescription medicines. It is also not recommended for people with severe kidney issues.\nMerck plans to ship hundreds of thousands of treatment courses in coming days and 1 million over the next few weeks. Pfizer plans to ship about 250,000 courses in the next month.\nAvailability of other treatments is the first consideration for doctors thinking of prescribing Merck's treatment, according to Patrizia Cavazzoni, the director of FDA's Center for Drug Evaluation and Research.\nThe FDA has authorized intravenous treatments, mostly for hospital use, called monoclonal antibodies but availability is limited and efficacy against the Omicron variant is lower.\nFDA official John Farley said during a press briefing that GlaxoSmithKline's and Vir Biotech's antibody drug - which has been shown to work against Omicron - is expected to be in short supply this winter.\nMerck said that its treatment had advantages over the Pfizer pill.\n\"It doesn't require any second drug to boost its efficacy, and you can give it in a variety of special patient populations, including people who have significant issues with liver function or kidney function,\" Nick Kartsonis, Merck's senior vice president of clinical research for vaccines and infectious diseases, told Reuters.\n\"This approval comes at the right time since more COVID-19 treatments are needed to supplement the vaccination effort, especially in light of variants of concern,\" said Cantor Fitzgerald analyst Louise Chen.\nNearly 62% of people in the United States are fully vaccinated, leaving many Americans unprotected against a wave of Omicron infections. Two doses of the highly successful vaccine from Pfizer Inc and BioNTech SE are only somewhat protective against infection with the Omicron variant while a third dose improves the immune response.\nMerck's and Pfizer's antiviral both work by preventing the virus from replicating. Merck's pill does so by introducing errors into the genetic code of the virus.\nSome of the FDA's experts have said that could lead to more troublesome variants.\nThere have also been some safety concerns around the drug because it may affect bone cartilage and growth.\nDue to that reason, Merck's drug is not authorized for use in patients younger than 18, the FDA said. The pill is not recommended for use during pregnancy, the agency added.\nThe agency advised that men of reproductive potential use a reliable method of birth control during treatment with molnupiravir, and for at least three months after the final dose.\nThe drug is meant to be taken twice a day - four pills each time - for five days, making a full treatment course 40 pills. The treatment was priced at about $700 per course in a deal with the U.S. government for up to 5 million courses.\nThe U.S. government has ordered 10 million courses of the Pfizer drug at a price of $530 per course compares to the deal with Merck for as many as 5 million courses of molnupiravir at a price of $700 per course.\nMerck has said molnupiravir, which helps prevent the virus from replicating, should be effective against any variant, including the new Omicron variant.","news_type":1},"isVote":1,"tweetType":1,"viewCount":472,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698380019,"gmtCreate":1640304910135,"gmtModify":1640305273060,"author":{"id":"4101174879260110","authorId":"4101174879260110","name":"gil dina","avatar":"https://static.tigerbbs.com/f87f0548663e1e1e6cfee22d9a835013","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698380019","repostId":"1102721082","repostType":4,"isVote":1,"tweetType":1,"viewCount":539,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691271645,"gmtCreate":1640216488696,"gmtModify":1640216488696,"author":{"id":"4101174879260110","authorId":"4101174879260110","name":"gil dina","avatar":"https://static.tigerbbs.com/f87f0548663e1e1e6cfee22d9a835013","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Oh no","listText":"Oh no","text":"Oh no","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691271645","repostId":"1104039472","repostType":4,"isVote":1,"tweetType":1,"viewCount":500,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691273446,"gmtCreate":1640216461102,"gmtModify":1640216461191,"author":{"id":"4101174879260110","authorId":"4101174879260110","name":"gil dina","avatar":"https://static.tigerbbs.com/f87f0548663e1e1e6cfee22d9a835013","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691273446","repostId":"2193920361","repostType":4,"repost":{"id":"2193920361","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1640185200,"share":"https://www.laohu8.com/m/news/2193920361?lang=&edition=full","pubTime":"2021-12-22 23:00","market":"us","language":"en","title":"Britain approves Pfizer-BioNTech shot for younger children","url":"https://stock-news.laohu8.com/highlight/detail?id=2193920361","media":"Reuters","summary":"LONDON, Dec 22 (Reuters) - Britain's medicines regulator on Wednesday approved use of the COVID-19 v","content":"<p>LONDON, Dec 22 (Reuters) - Britain's medicines regulator on Wednesday approved use of the COVID-19 vaccine from partners Pfizer and BioNTech for children aged 5 to 11 years, after the watchdog found the shot was safe and effective.</p>\n<p>The country's vaccines committee advised that children in the age group who were in a clinical risk group should be offered the shot.</p>\n<p>The children will receive two 10-microgram doses of the Pfizer-BioNTech vaccine - a third of the adult dose - with an interval of eight weeks between the first and second doses, the Joint Committee on Vaccination and Immunisation said.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Britain approves Pfizer-BioNTech shot for younger children</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBritain approves Pfizer-BioNTech shot for younger children\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-22 23:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>LONDON, Dec 22 (Reuters) - Britain's medicines regulator on Wednesday approved use of the COVID-19 vaccine from partners Pfizer and BioNTech for children aged 5 to 11 years, after the watchdog found the shot was safe and effective.</p>\n<p>The country's vaccines committee advised that children in the age group who were in a clinical risk group should be offered the shot.</p>\n<p>The children will receive two 10-microgram doses of the Pfizer-BioNTech vaccine - a third of the adult dose - with an interval of eight weeks between the first and second doses, the Joint Committee on Vaccination and Immunisation said.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","PFE":"辉瑞","BK4534":"瑞士信贷持仓","BK4568":"美国抗疫概念"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193920361","content_text":"LONDON, Dec 22 (Reuters) - Britain's medicines regulator on Wednesday approved use of the COVID-19 vaccine from partners Pfizer and BioNTech for children aged 5 to 11 years, after the watchdog found the shot was safe and effective.\nThe country's vaccines committee advised that children in the age group who were in a clinical risk group should be offered the shot.\nThe children will receive two 10-microgram doses of the Pfizer-BioNTech vaccine - a third of the adult dose - with an interval of eight weeks between the first and second doses, the Joint Committee on Vaccination and Immunisation said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":845,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691279370,"gmtCreate":1640216333115,"gmtModify":1640216333115,"author":{"id":"4101174879260110","authorId":"4101174879260110","name":"gil dina","avatar":"https://static.tigerbbs.com/f87f0548663e1e1e6cfee22d9a835013","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691279370","repostId":"2193192720","repostType":4,"isVote":1,"tweetType":1,"viewCount":714,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}